The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy.
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Telix Pharmaceuticals
Speakers' Bureau - Ipsen
Research Funding - Pfizer (Inst)
 
Johannes van der Mijn
No Relationships to Disclose
 
Niels Graafland
No Relationships to Disclose
 
Johannes van Thienen
No Relationships to Disclose
 
Sofie Wilgenhof
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Brunolf Lagerveld
No Relationships to Disclose
 
Patricia Zondervan
No Relationships to Disclose
 
Reindert Van Moorselaar
No Relationships to Disclose
 
Mark Kockx
Leadership - CellCarta
Stock and Other Ownership Interests - CellCarta
 
Pieter-Jan Van Dam
Employment - CellCarta
 
Pieter Mestdagh
Employment - CellCarta
 
Bernadett Szabados
Honoraria - J&J; Merck Serono; MSD; Pfizer
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Christian Blank
Stock and Other Ownership Interests - Immagene; Signature Oncology
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
John Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AstraZeneca (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); CureVac; Eisai (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Sastra Cell Therapy; T-Knife (Inst); Third Rock Ventures; Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)